Factors Associated with Phlebitis and Venous Pain due to Intravenous Injection of Epirubicin Hydrochloride
スポンサーリンク
概要
- 論文の詳細を見る
Anthracyclines play an important role in the treatment of breast cancer and various regimens containing doxorubicin (A) and epirubicin hydrochloride (E), e.g., AC (doxorubicin+cyclophosphamide), EC (epirubicin hydrochloride+cyclophosphamide), and FEC (fluorouracil+epirubicin+cyclophosphamide) are widely used in clinical oncology. However, anthracyclines frequently cause inflammation or pain at the site of injection and along blood vessels. To determine the cause of phlebitis and venous pain due to these agents, we designed an experimental study to investigate factors considered to be associated with these symptoms, such as titratable acidity, osmotic pressure, and pH, for the 2 epirubicin preparations available for the FEC regimen : Farmorubicin® (freeze-dried formulation) and Farmorubicin® RTU (ready-to-use injection solution). We compared Farmorubicin® and Farmorubicin® RTU when diluted with various concentrations of saline, 5% glucose, and distilled water, and with or without dexamethasone. The titratable acidity of Farmorubicin® RTU was 3.4 mEq/L, far less than the 7 mEq/L reported to sometimes cause phlebitis and venous pain, which suggests that the titratable acidity of Farmorubicin® RTU is not connected with phlebitis or venous pain. The pHs of Farmorubicin®, Farmorubicin® RTU and dexamethasone were 4.5 to 6.0, 2.5 to 3.5, and 7.0 to 8.5, respectively. The osmotic pressures of Farmorubicin®, Farmorubicin® RTU, and dexamethasone were all 282 mOsm/kg. Thus pH could be modified by adding small amounts of dexamethasone, which is normally used prior to FEC therapy to avoid nausea, vomiting, and hypersensitivity to Farmorubicin® RTU, and doing this might prevent the phlebitis and venous pain that occur during injection of Farmorubicin® RTU.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)